Full Press Release Details
NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a late-stage clinical development company focused on a rich pipeline of innovative immuno-oncology cancer therapies, announced today that senior management, led by Dr. Lan Huang, Ph.D., Chairman and CEO, will be attending the Jefferies 2017 Healthcare Conference, to be held at the Grand Hyatt Hotel in New York City from June 6 to June 9, 2017. Management will be available for one-on-one meetings at the Conference.
Investors attending the conference who wish to meet with management for a one-on-one meeting should notify their appropriate contact or e-mail healthcareconference@jefferies.com.
BeyondSpring is a global clinical stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with Fred Hutchinson Cancer Research Center and University of Washington. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and Phase 2/3 clinical trials in the prevention of chemotherapy-induced neutropenia. BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.
Studies on Plinabulin's method of action indicate that Plinabulin activates GEF-H1, a guanine nucleotide exchange factor. GEF-H1 activates downstream transduction pathways leading to the activation of the protein c-Jun. Activated c-Jun enters the nucleus of dendritic cells to upregulate immune-related genes, which contributes to the up-regulation of a series of genes leading to dendritic cell maturation, T-cell activation and other effects that prevent neutropenia.